JNJ · News · 20261021N
Quarterly Earnings Performance
JOHNSON & JOHNSON · 2026-10-21 · Importance 59 · Surprise 82 · No source text
Third-quarter sales increased 5.9% year over year to $25.4 billion. Adjusted EPS declined 7.5% to $2.59, while reported EPS fell to $0.09 from $2.12. The reported-EPS decline reflected a one-time charge related to a proposed talc settlement and two deals. Innovative Medicines provided the primary earnings support, while Medical Devices remained the weaker business according to the report.
Key facts
- Johnson & Johnson reported a 96% GAAP net earnings drop year-over-year, primarily due to a one-time charge for talc litigation resolution. source
- Reported earnings per share dropped to $0.09 from $2.12 after a one-time charge tied to a proposed talc settlement and two deals. source
- Third-quarter sales grew 5.9% to $25.4 billion. source
- Adjusted earnings per share fell 7.5% to $2.59. source
- Shares of Johnson & Johnson returned -3.7% over the past month. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +5.6% | Third-quarter sales grew 5.9% to $25.4 billion. |
| net_income | negative | realized | — | Reported earnings per share dropped to $0.09 from $2.12 after a one-time charge tied to a proposed talc settlement and two deals. |